OptimEyes has developed a patent-pending drug delivery technology that entraps drug in its core and binds to the surface of the eye using GRAS compounds. By entrapping a drug at their core, these particles facilitate the controlled release of this drug, greatly enhancing its clinical efficacy. By binding to the ocular surface, this technology greatly increases residence time, allowing the controlled release of a therapeutic to take place over several days and reducing dosing frequency. Ultimately, by providing an appropriate amount of drug directly to target tissues over a long period of time, we can fundamentally improve ocular therapies delivered via eye drops and improve patient compliance
and convenience with fewer doses required.
The active ingredient in Restasis, the DED market leader, is an off-patent drug Cyclosporin A (CycA). We have used CycA as our lead therapeutic to demonstrate the advantages of our
technology. In laboratory testing, we have shown the particles on the eye at least 12x longer than Restasis and release drug for over a week, reducing the dosage from twice daily to twice weekly. We also expect our formulation has eliminated the burning sensation common with Restasis, as it is an aqueous formulation instead of an emulsion. No toxicity with the particles has been observed in animal models, demonstrating safety in vivo.